Alzheimer's Disease

Emory Alzheimer's Disease Research Center Honor Research Registry

James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center

Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center

Link to study flyer »

The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking.    By joining Honor you will learn about new research studies that are seeking volunteers.  You will also receive our newsletter and invitations to educational events. 

All Honor volunteers must have a “study partner” accompany them to their research visit.  Your study partner will be asked questions about your memory and thinking.  They will also be asked about your day to day functioning.  A study partner is someone who has at least 10 hours of contact with you each week.

For more information about this research study, please call Erin Carter at 404-712-6838 or email erin.carter@emory.edu.


AbbVie

James Lah, MD, PhD

2-year study examining the safety and e cacy of an infusion of an antibody to the tau protein in subjects with a diagnosis of mild-to moderate Alzheimer’s disease. Tau is one of the proteins involved in cellular destruction in AD. Participants will be asked to undergo a PET scan, multiple MRIs, lumbar puncture, blood draws, and cognitive testing. 

For more information about this research study, please call Rebekah Rogers at 404-712-4234 or email rebekah.d.rogers@emory.edu.

Link to study website »


ADMET-2

Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology

A 6-month study designed to treat apathy in persons with a diagnosis of Alzheimer's disease. Participants will take 1 tablet of study medication daily. Participants will come to Emory for 7 visits and undergo the following procedures: ECG, cognitive testing, blood draws.

For more information about this research study, please call Tamara Attis at 404-712-6914 or email tattis@emory.edu.


ADNI-3

Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology

Long-term study (2-4 years) being conducted as part of the Alzheimer’s Disease Neuroimaging Initiative to characterize changes in the brain associated with MCI and AD. Subjects will under multiple MRI and PET scans, lumbar puncture, blood draws and cognitive testing. 

For more information about this research study, please call Becky Byram at 404-712-0195 or email rbyram@emory.edu.


AVID Autopsy

Link to study result »

6-month study to evaluate a new technique for measuring one of the proteins (tau) involved in Alzheimer’s disease. Participants will be asked to undergo a PET scan using a new technique and then, upon death, undergo autopsy to validate the accuracy of the PET scan measurements. Participation in this study will help to advance our understanding of the cause and course of Alzheimer’s disease. 

For more information about this research study, please call Erin Carter at 404-712-6838 or email erin.carter@emory.edu.


CEDAR

Ihab Hajjar, MD

Link to study flyer »

CEDAR is examing the effects of candesartan vs placebo in mild cognitive impairment and Alzheimer’s disease. The study is recruiting people who are 50 years of age or older who have early or mild memory difficulties, do not have high blood pressure and do not take blood pressure medications. Study personnel will invite you to come to Emory for an evaluation to check if you are eligible. 

For more information about this research study, please call Maureen Okafor at 404-712-2881 or email m.o.okafor@emory.edu.

Link to study website »


CREAD

Allan Levey, MD, PhD

This clinical trial will test the experimental drug crenezumab in people with early to mild Alzheimer's disease. Investigators will assess the drug's safety and efficacy and evaluate any changes in participants' dementia rating and performance on neuropsychological tests.

For more information about this research study, please call Phyllis Vaughn at 404-712-6901 or email pvaughn@emory.edu.

Link to study website »


Memory and Aging in African Americans and Caucasians

For more information about this research study, please call William Hu at 404-727-4174 or email wthu@emory.edu.


NeuroVision

This is a 2-day study of amyloid imaging in the retina. This proof-of-concept study is for people with normal cognition or MCI, AD or other neurodegenerative disease. This is a brief study in which participants will be asked to ingest the spice curcumin for 2 days. Curcumin binds to the protein associated with Alzheimer’s disease, and it is possible to visualize the protein by looking into the eyes. Photographs of the eyes will be after 2 days of ingesting curcumin. The pupils of the eyes will be dilated for this study.

For more information about this research study, please call CeeCee Manzanares at 404-727-9324 or email cmanzan@emory.edu.


SERENE

A 3-month study of the drug pimavanserin for the treatment of agitation and aggression in patients with probable Alzheimer’s disease. The study requires 6 clinic visits, during which the participant will undergo the following procedures: cognitive testing, blood draws, MRI, physical and neurological exams. The treatment is 1 tablet taken 1 time per day. This is a placebo-controlled study with an open-label extension, which means that all participants have the opportunity to receive the active drug.

For more information about this research study, please call Becky Byram at 404-712-0195 or email rbyram@emory.edu.


Tau Imaging (GN30009)

Longitudinal observation study to evaluate a new technique for imaging the tau protein in patients with prodromal, mild and moderate Alzheimer’s disease as compared to healthy volunteers. This study involves travel to New Haven, CT every 6 months for 18 months for 4 trips altogether. All travel expenses for the participant and caregiver are covered by the study sponsor.  In addition, the participant must come to Emory for 6 visits to undergo 1 PET scan, a lumbar puncture, MRI, blood draws, and cognitive testing.

For more information about this research study, please call Deborah Westover at 404-712-6807 or email dwestov@emory.edu.


TRIAD

A 4-month study of a treatment to reduce agitation in patients with Alzheimer’s disease. The study requires 7 clinic visits, during which the participant will undergo the following procedures: cognitive testing, blood draws, physical and neurological exams. The treatment is a small tablet taken daily. 

For more information about this research study, please call Andrea Kippels at 404-712-6868 or email ajkippe@emory.edu.